Compared with the conventional tumor markers CEA and CA19-9, our miRNA signature consistently demonstrated superior diagnostic performance for all-stage GC (AUC: signature, 0.86; CEA, 0.65; CA19-9, 0.67; P < .001 in DeLong tests) (eTable 8, eFigure 7 in the Supplement). The gene discussed is CEACAM5; the disease is neoplasm.